The apolipoproteins, immunoglobulins, and haptoglobin were assayed initially by immunonephelometry with a BNA and a BN II (Behring Nephelometer; Dade-Behring) and on a second sample with a BN 100 and again with a BN II. The BN II is operated at 37°C, the others at room temperature (ϳ23°C). The results are shown in Table 1 . The BNA (room temperature) appeared to overestimate all proteins except IgM (2.94 g/L), which was underestimated in the crude serum; after the crude serum was diluted, the IgM concentration was 60 g/L. The serum cholesterol value was consistent for apolipoproteins A-I and B with the BN II (37°C) procedures but not with the room temperature methods.
To determine the frequency of this interference by monoclonal immunoglobulins, a double-blind study was conducted that involved determining the proteins with both a BN 100 and a BN II. Among 70 sera with monoclonal immunoglobulins (38 with monoclonal IgM, 12 with monoclonal IgA, 20 with monoclonal IgG), comparable interference occurred only for the index patient (Table 1B) .
We therefore conclude that the monoclonal IgM could influence the BNA and BN 100 procedures. We (5 ) and others (1) (2) (3) (4) 6 ) have reported interference between monoclonal IgM and latex particles in the immunonephelometric assay of C-reactive protein, antistreptolysin O, and ferritin. However, latex particles and supplement reagents for precipitation were not used in the immunoglobulin and haptoglobin assays by the BNA, BN 100, or BN II procedures. This rules out any dependent unselective precipitation of the reagents.
Thus, after excluding a cryoglobulin and the reagents as causal factors of the discrepancy in the presented data, we must conclude that the monoclonal IgM was the primary reason for the present unselective precipitation during the immunonephelometric assays of proteins, which did not occur when the temperature was increased to 37°C. We point out the difficulty in taking into account this rare interference be-cause it occurred only once among 38 samples containing monoclonal IgM checked in our laboratory.
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To the Editor: Jung et al. (1 ) reported an apparent gap between total serum prostatespecific antigen (t-PSA) and the sum of free PSA (f-PSA) plus ␣ 1 -antichymotrypsin-PSA (ACT-PSA) in patients with prostate carcinoma (PCa) but not in those with benign prostatic hypertrophy (BPH). The gap may be attributable to a variety of technical artifacts such as different recognition of multiple forms of f-PSA or t-PSA in the two groups of patients or the lack of equimolarity of the tests used (1 ) . Of more interest, however, is the suggestion by the authors that the appearance of this "PSA gap" reflects an increase in minor PSA complexes in PCa patients that their assay for ACT-PSA does not detect. Indeed, they suggest that such an observation contradicts the high expectations (2 ) for the determination of ACT-PSA or the ratio of ACT-PSA to t-PSA to improve the differentiation between PCa and BPH.
The authors refer to a novel approach to the measurement of complexed forms of PSA (3 ) as a possible solution to the potential problem of minor PSA forms. This complexed PSA (c-PSA) assay is now available commercially for the Bayer Immuno-1 automated immunochemistry analyzer (Bayer Diagnostics). We recently used this assay along with measurements of t-PSA (Bayer Im-muno-1), f-PSA (Abbott IMx; Abbott Diagnostics), and the ratio of f-PSA to t-PSA (Abbott IMx, both assays) on a prospective basis in men referred to a hospital urology clinic with t-PSA measurements between 3.0 and 22.0 g/L. Of the 79 consecutive patients assessed to date, 21 (27%) were diagnosed with PCa by a combination of clinical presentation, digital rectal examination, prostatic volume, and transrectal ultrasoundguided prostatic biopsy (all patients). We found no gap between t-PSA (Bayer Immuno-1 assay) and the sum of f-PSA (Abbott IMx assay) and c-PSA (Bayer Immuno-1 assay) in patients with PCa or BPH. The sum of f-PSA and c-PSA was 100.6% (SD, 7.6%) of t-PSA in the BPH patients and 100.5% (SD, 6.2%) in the PCa patients.
We believe, therefore, that our data showing the lack of a PSA gap in both PCa and BPH patients, along with the observations of Jung et al. (1 ) , may help solve the conundrum of why ACT-PSA does not perform as well as predicted.
